Pulmonary arterial hypertension at its core is a disease of abnormal lung blood vessel behavior. While our currently available therapies have successfully improved the quality of life of our patients and extended their life expectancy, we still have a long way to go.  PAH patients unfortunately still often face progressive symptoms over time. What is the C76 Molecule? The FDA … [Read more...]

After six years, the FREEDOM-EV clinical trial has finished and preliminary results have been released. This study included patients with PAH who were already on a single oral therapy (either a PDE 5 inhibitor or an ERA). They were then randomized to have either a placebo or Orenitram added to their regimen.  Although we don’t have all of the final results, United Therapeutics … [Read more...]

After many years under patent protection, the generic medication Tadalafil will soon be available. What does this mean for patients? Hopefully generic Tadalafil will be much less expensive than Adcirca.  We can look back at what happened with a similar medicine, Revatio, when it went generic as sildenafil. Pricing We don’t know precise pricing but we expect deep discounts … [Read more...]

Bellerophon announced that their phase 3 clinical trial using portable nitric oxide in patients with PAH has been stopped.  The trial was stopped early after an analysis of data gathered so far showed no evidence of efficacy (the inhaled medication was not effective).  There did not appear to be a safety problem. This clinical trial was exciting as very low nitric oxide … [Read more...]

It is finally here! The Food and Drug Administration approved Remodulin in its implantable delivery system for treatment of Pulmonary Arterial Hypertension. We have been providing updates on the 8-year study that investigated the use of an implanted pump to deliver Remodulin removing the need for external pumps and are excited to announce it is finally approved. The pump … [Read more...]